U.S. markets closed

  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     

  • Dow 30

    33,963.84
    -106.58 (-0.31%)
     

  • Nasdaq

    13,211.81
    -12.18 (-0.09%)
     

  • Russell 2000

    1,776.50
    -5.32 (-0.30%)
     

  • Crude Oil

    90.33
    +0.70 (+0.78%)
     

  • Gold

    1,944.90
    +5.30 (+0.27%)
     

  • Silver

    23.82
    +0.13 (+0.56%)
     

  • EUR/USD

    1.0647
    -0.0015 (-0.14%)
     

  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     

  • GBP/USD

    1.2240
    -0.0054 (-0.44%)
     

  • USD/JPY

    148.3600
    +0.7970 (+0.54%)
     

  • Bitcoin USD

    26,576.40
    -39.45 (-0.15%)
     

  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     

  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     

  • Nikkei 225

    32,402.41
    -168.62 (-0.52%)
     

Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

Vandana Singh
·1 min read

  • Inventiva (NASDAQ: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.

  • Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the potential to receive up to $290 million in milestone payments.

  • Related: FDA Gives Green Signal To Inventiva's Mid-Stage Lanifibranor Study In NASH Patients.

  • In its 1H earnings release, Inventiva said it targets the last patient's first visit for NATiV3 Phase 3 trial of lanifibranor in patients with NASH for H2 2023 vs. 1H 2023, with topline data from part 1 of the study now targeted for 2H of 2025.

  • The company says the delay is primarily due to a higher than initially projected screen failure rate resulting in a slower than anticipated enrollment rate hit by the Russia-Ukraine war and the pandemic.

  • With a cash balance of €76.4 million, Inventiva's Cash runway extended through Q4 2023, including the expected $12 million upfront payment from Sino Biopharm and the €25 million from the EIB credit facility.

  • Price Action: IVA shares trading higher by 22.10% higher at $4.80 during premarket trading on Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.